|   LifeSciVC

Strategic Planning In Biotech During A Pandemic Crisis

By Bruce Booth, DPhil, Partner

In the throes of a full COVID-19 pandemic, most business leaders’ top priority is rightfully the health and safety of their employees, families, and communities. Even though business disruptions are significant and overwhelming, the primary efforts focused on both safety and the control of the spread of SARS-CoV-2, like social distancing and working remotely, are paramount.

Read more.


  |   From the Trenches

Coming Together While Staying Apart

I have never participated in trench warfare and I am sure it was pretty grim for those who lived and suffered through it. I have spent plenty of time however ‘in the trenches’ in biotech. Just like the stories of war, I have made it through the tough times because of the comradery of colleagues who are right there beside me, covered in mud and blood, fighting. We tend to find the presence of others comforting so one of the most difficult things about the current COVID-19 pandemic is that we need to deal with it while being physically separated from our team.

This blog was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Core (Values) Workout

Like many middle-aged weekend warriors, I’ve been recently sidelined by injury simply through doing what I’ve regularly done: run. Injury stopped me from running last fall and I’ve since seen orthopods and running experts galore. But it’s been the physical therapists who’ve really laid the hammer home: “Jeb, you need to work on your core.” To quote (in what must be a first for the LifeSciVC blog) Shape magazine, “Your core is your entire support system… Core strength is crucial in every movement you do.”

This blog was written by Jeb Keiper, CEO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   LifeSciVC

BioPharma M&A Drives More Efficient Resource Allocation

By Bruce Booth, DPhil, Partner

M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups.

Read more.


  |   In the News

Akrevia no more, Xilio Therapeutics bags $101M for I-O programs

As it gears up to move its immuno-oncology programs into the clinic, Akrevia Therapeutics has reeled in a $100.5 million series B and changed its name to Xilio Therapeutics to mark its transition from a research-focused company to an R&D-stage one.

Read more.